GlassScriptPhysician profile
Aimee J Torres
NPI 1801324892
$6,072.92
in general payments reported to CMS, 2019-2025
24 companies · $1,371 in 2025
The $1,371 reported for 2025 was more than what 86% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,360 · 2022: $895 · 2023: $853 · 2024: $1,594 · 2025: $1,371.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,634 · Education: $184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,633.65 |
| Education | $183.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,220.11 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $678.16 | 2021-2025 | Xifaxan, Plenvu, Trulance |
| Janssen Biotech, INC. | $580.58 | 2023-2025 | Tremfya, Stelara, Simponi |
| Qol Medical, LLC | $465.89 | 2021-2025 | Sucraid, Sucraid |
| Ardelyx, INC. | $391.28 | 2022-2025 | Ibsrela |
| Gilead Sciences, INC. | $385.49 | 2021-2025 | Epclusa |
| Takeda Pharmaceuticals U.S.A., INC. | $382.51 | 2021-2025 | Gattex, Eohilia, Entyvio |
| Pfizer INC. | $282.84 | 2023-2025 | |
| Celgene Corporation | $280.86 | 2021-2024 | Zeposia |
| Phathom Pharmaceuticals, INC. | $247.17 | 2023-2025 | Voquezna |
| Ironwood Pharmaceuticals, INC | $181.70 | 2021-2024 | Linzess |
| Redhill Biopharma INC. | $174.96 | 2021-2025 | Talicia |
| Madrigal Pharmaceuticals | $158.22 | 2025 | Rezdiffra |
| Genzyme Corporation | $129.31 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $109.69 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $98.50 | 2021-2023 | Ocaliva |
| Nestle Healthcare Nutrition INC. | $93.94 | 2021-2023 | |
| Aimmune Therapeutics, INC. | $48.15 | 2024-2025 | Zenpep, Vowst |
| Medtronic, INC. | $41.81 | 2023 | Ligasure |
| Ipsen Biopharmaceuticals, INC | $32.17 | 2025 | Iqirvo |
| Braintree Laboratories, INC. | $31.17 | 2021-2024 | Suflave, Sutab |
| Lilly USA, LLC | $25.60 | 2024 | Omvoh |
| Shield Therapeutics INC | $19.59 | 2024 | |
| W. L. Gore & Associates, INC. | $13.22 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aimee Torres listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.